VABYSMO (Faricimab) Clinical, Regulatory And Commercial Intelligence Report 2026
Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "VABYSMO Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.
The report provides a comprehensive assessment of VABYSMO (faricimab) across the seven major markets: the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. Covering the 2020-2034 period, the report evaluates historical performance, current utilization, market dynamics and forecast sales across approved and potential retinal disease indications.
Strong Commercial Momentum Supports VABYSMO Market Growth
VABYSMO has become one of the fastest-growing ophthalmology drugs worldwide. Global sales reached approximately CHF 3.9 billion in 2024, representing year-over-year growth of 68%. Sales totaled CHF 2.07 billion during the first half of 2025, an increase of 18% compared with the same period in the previous year. This performance established VABYSMO as a multibillion-dollar blockbuster within approximately three years of launch.
Commercial growth is being supported by increasing physician adoption, broader utilization across major retinal diseases and market share gains in the anti-VEGF treatment segment. VABYSMO's ability to inhibit both vascular endothelial growth factor A and angiopoietin-2 differentiates it from VEGF-only therapies. Its potential for extended dosing intervals may also reduce treatment burden and support patient adherence, contributing to prescription growth and competitive positioning.
VABYSMO is approved for neovascular age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion. Depending on the indication, treatment response and applicable prescribing information, eligible patients may receive maintenance dosing at extended intervals after initial loading doses.
Recent VABYSMO Clinical Developments
In September 2025, Roche announced new VABYSMO data from the AVONELLE-X and SALWEEN studies at the 25th Euretina Congress in Paris. Results from the open-label AVONELLE-X study reinforced the efficacy, safety and durability profile of VABYSMO over four years in neovascular age-related macular degeneration. In the single-arm SALWEEN study, VABYSMO delivered clinically meaningful vision gains and retinal drying over one year in patients with polypoidal choroidal vasculopathy, a subtype of neovascular age-related macular degeneration that is particularly prevalent in Asia.
VABYSMO Drug and Clinical Overview
Developed by Genentech, a member of the Roche Group, VABYSMO is a bispecific monoclonal antibody administered by intravitreal injection at a dose of 6 mg/0.05 mL. It received initial approval from the US Food and Drug Administration in 2022. The therapy targets VEGF-A and Ang-2 to address neovascularization, vascular leakage and retinal vascular instability.
Clinical programs including TENAYA and LUCERNE in neovascular age-related macular degeneration, YOSEMITE and RHINE in diabetic macular edema, and BALATON and COMINO in retinal vein occlusion have supported its efficacy, anatomical outcomes and dosing durability. The report reviews available safety findings, including common ocular adverse events and clinically significant risks requiring appropriate monitoring.
Scope of the VABYSMO Market Report
- Historical and forecast VABYSMO sales through 2034 across the seven major markets. Market analysis for diabetic macular edema, retinal edema and neovascular age-related macular degeneration. Assessment of potential opportunities in choroidal neovascularization and diabetic retinopathy. Product analysis covering mechanism of action, dosage, administration and clinical development. Regulatory milestones, development activities and anticipated market-entry scenarios. Pricing, reimbursement, treatment cost and regional market-access considerations. Patent landscape, potential generic or biosimilar entry and associated pricing implications. SWOT analysis, analyst perspectives and factors influencing future adoption. Competitive intelligence covering marketed products and late-stage emerging therapies.
VABYSMO Market Forecast and Competitive Landscape
The report analyzes VABYSMO's market positioning relative to established retinal disease treatments and emerging pipeline candidates. It examines prescription trends, competitive displacement, clinical differentiation and the potential effect of future product launches on VABYSMO sales. Coverage also includes competing drugs in development, anticipated launch timelines, commercial partnerships, licensing agreements and relevant merger and acquisition activity.
Revenue forecasting evaluates the projected VABYSMO market size, peak sales potential, indication-level demand, pricing strategies and reimbursement conditions. Forecast assumptions account for adoption rates, eligible patient populations, dosing patterns, regulatory developments, competition and geographic variations in treatment access.
Key Report Insights
- VABYSMO sales performance and growth drivers across major ophthalmology markets. Current and forecast market opportunities by approved and potential indication. Clinical trial status, study timelines and relevant efficacy and safety findings. Regulatory designations, approvals and geographic expansion opportunities. Competitive threats from marketed therapies and late-stage pipeline products. Cost-effectiveness, treatment duration and regional cost-per-patient variations. Potential barriers involving pricing, reimbursement, safety, competition and market access.
The analysis is designed to support pharmaceutical companies, investors, healthcare organizations and other stakeholders in evaluating VABYSMO's sales outlook through 2034. By combining market forecasts with clinical, regulatory, pricing and competitive intelligence, the report provides actionable insights for portfolio planning, commercial strategy and investment decision-making within the global retinal disease treatment market.
Key Topics Covered
1. Report Introduction
2. VABYSMO Overview in approved indications like Diabetic macular oedema, Retinal oedema, and Wet age-related macular degeneration; as well as potential indication like Choroidal neovascularisation and Diabetic retinopathy
2.1. Product Detail
2.2. VABYSMO Clinical Development
2.2.1. VABYSMO Clinical studies
2.2.2. VABYSMO Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. VABYSMO Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging VABYSMO Therapies)
5. VABYSMO Market Assessment
5.1. VABYSMO Market Outlook in approved and potential indications
5.2. 7MM Analysis
5.2.1. VABYSMO Market Size in the 7MM for approved and potential indications
5.3. Country-wise Market Analysis
5.3.1. VABYSMO Market Size in the United States for approved and potential indications
5.3.2. VABYSMO Market Size in Germany for approved and potential indications
5.3.3. VABYSMO Market Size in France for approved and potential indications
5.3.4. VABYSMO Market Size in Italy for approved and potential indications
5.3.5. VABYSMO Market Size in Spain for approved and potential indications
5.3.6. VABYSMO Market Size in the United Kingdom for approved and potential indications
5.3.7. VABYSMO Market Size in Japan for approved and potential indications
6. VABYSMO SWOT Analysis
7. Analyst's Views
8. Appendix
8.1. Bibliography
8.2. Report Methodology
List of Tables
Table 1: VABYSMO, Clinical Trial Description, 2023
Table 2: VABYSMO, General Description
Table 3: Competitive Landscape (Marketed Therapies)
Table 4: Competitive Landscape (Emerging Therapies)
Table 5: VABYSMO's pricing and cost Assumptions
Table 6: VABYSMO's Sales Analysis in the 7MM, in USD million (2020-2034)
Table 7: VABYSMO Market Size in the US, in USD million (2020-2034)
Table 8: VABYSMO Market Size in Germany, in USD million (2020-2034)
Table 9: VABYSMO Market Size in France, in USD million (2020-2034)
Table 10: VABYSMO Market Size in Italy, in USD million (2020-2034)
Table 11: VABYSMO Market Size in Spain, in USD million (2020-2034)
Table 12: VABYSMO Market Size in the UK, in USD million (2020-2034)
Table 13: VABYSMO Market Size in Japan, in USD million (2020-2034)
List of Figures
Figure 1: VABYSMO's Sales Analysis in the 7MM, USD million (2020-2034)
Figure 2: VABYSMO Market Size in the United States, USD million (2020-2034)
Figure 3: VABYSMO Market Size in Germany, USD million (2020-2034)
Figure 4: VABYSMO Market Size in France, USD million (2020-2034)
Figure 5: VABYSMO Market Size in Italy, USD million (2020-2034)
Figure 6: VABYSMO Market Size in Spain, USD million (2020-2034)
Figure 7: VABYSMO Market Size in the United Kingdom, USD million (2020-2034)
Figure 8: VABYSMO Market Size in Japan, USD million (2020-2034)
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment